相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial
Elizabeth R. Volkmann et al.
RHEUMATOLOGY (2022)
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
Masataka Kuwana et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
Anna-Maria Hoffmann-Vold et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
Kristin B Highland et al.
Lancet Respiratory Medicine (2021)
Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease
David Roofeh et al.
ARTHRITIS & RHEUMATOLOGY (2021)
PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)
R. Spiera et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Dinesh Khanna et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database
Camelia Frantz et al.
AUTOIMMUNITY REVIEWS (2020)
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Dinesh Khanna et al.
LANCET RESPIRATORY MEDICINE (2020)
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
Anna-Maria Hoffmann-Vold et al.
LANCET RHEUMATOLOGY (2020)
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
Wanlong Wu et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort
Anna-Maria Hoffmann-Vold et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
Lutz Wollin et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts
Elizabeth R. Volkmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Mapping and predicting mortality from systemic sclerosis
Muriel Elhai et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort
Shervin Assassi et al.
ARTHRITIS RESEARCH & THERAPY (2010)
分享论文
